Compare

Larazotide vs LL-37

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Larazotide

1343 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-14
Mood
-82
Focus
-135
Sleep quality
-142
Lean mass
-143

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-98
Fatigue
-2
Nausea
10
Water retention
-146
Appetite loss
-143

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
9
5+ mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects13larazotide26

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 295 repeat reporters

LL-37

1825 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
64
Digestive comfort
131
Skin appearance
49
Appetite control
84
Energy
88

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
160
Flushing
30
Headache
14
GI discomfort
79
Dizziness
87

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.025–2 mg

0.025–0.05 mg
9
0.05–0.1 mg
17
0.1–0.2 mg
25
0.2–0.4 mg
32
0.4–0.6 mg
25
0.6–1 mg
18
1–2 mg
7

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing29stacking37side effects15ll-378

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 402 repeat reporters

Sources (8)

Published sources linked on the Larazotide and LL-37 wiki pages.

  1. PubMed

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

    Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015

    Source
    Wiki study page →
  2. PubMed

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026

    Source
    Wiki study page →
  3. PubMed

    The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

    Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016

    Source
    Wiki study page →
  4. PubMed

    LL-37, the only human member of the cathelicidin family of antimicrobial peptides

    Vandamme D, Landuyt B, Luyten W, et al. Biochim Biophys Acta. 2012

    Source
    Wiki study page →
  5. PubMed

    The antimicrobial peptide LL-37 inhibits biofilm formation

    Dean SN, Bishop BM, van Hoek ML. BMC Microbiol. 2011

    Source
    Wiki study page →
  6. PubMed

    Rosacea: Pathogenesis and Therapeutic Correlates

    Geng RSQ, Bourkas AN, Mufti A, et al. Journal of cutaneous medicine and surgery. 2024

    Source
    Wiki study page →
  7. PubMed

    LL-37 antimicrobial peptide: Molecular characterisation and its role in oral health and disease-A narrative review

    Soman D, P J, Cm M, et al. Archives of oral biology. 2026

    Source
    Wiki study page →